This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Esperion Therapeutics, Inc.
Drug Names(s): apoA1 mimetic, apolipoprotein A1-4WF
4WF is a next generation synthetic HDL therapy designed to preserve the function of HDL and its primary apolipoprotein, apoA-I, and to deliver oxidation-resistant synthetic HDL therapy via an injection as opposed to intravenous infusion.
Research demonstrates that HDL becomes dysfunctional and loses its cholesterol acceptor and anti-inflammatory activity through myeloperoxidase mediated enzymatic oxidation. 4WF is designed to resist this.
In June 2011, Esperion acquired the exclusive worldwide rights to 4WF from the Cleveland Clinic Foundation. Esperion is obligated to make certain royalty and milestone payments (consisting of cash and common stock) to CCF, including a minimum annual cash payment of $50,000 during years when a milestone payment is not met.
On December 7, 2011, Esperion issued an aggregate of 20,000 shares of their common stock to The Cleveland Clinic Foundation as consideration under an Exclusive License Agreement, dated as of December 7, 2011, pursuant to which they licensed certain intellectual property from The Cleveland Clinic Foundation related to their 4WF development program.
Pink Sheet FDA Performance Tracker: CDER Approvals
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: